A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia (NCT01564784)
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin (CMC-544) versus investigator’s choice of chemotherapy.
- Phase: III
- Estimated Enrollment: 325
- Start: August 2012
- Estimated Completion: March 2017
- Last verified: June 2015
Last Editorial review: July 29, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.